Taille du marché mondial, prévisions et tendances marquantes sur 2024-2036
Cardiac Rhythm Management Devices Market size was over $18 billion in 2023 and is expected to exceed $40 billion by the end of 2036, growing at a CAGR of over 7% during the forecast period from 2024 to 2036. In 2024, the Cardiac Rhythm Management Devices industry size is estimated at $19 billion.
The need for effective treatment has increased due to the increasing prevalence of cardiovascular disorders, including atrial fibrillation, cardiac arrhythmias, and heart failure. The National Library of Medicine observed that 10,951,403 deaths due to CVD (heart disease, 16.9% stroke) occurred between 2010 and 2022. The aging population, which is more prone to heart conditions, has also contributed to the growth of the cardiac rhythm management devices market. The development of the market has also been greatly facilitated by technological advancements. The accuracy and efficiency of these devices have increased due to advances in wireless communication, intelligent algorithms, and reduction in devices. The treatment of cardiac rhythm abnormalities has also been completely transformed by the advent of pacemakers, cardiac resynchronization therapy (CRT) devices, and implantable cardioverter-defibrillators.
Secteur des dispositifs de gestion du rythme cardiaque : facteurs de croissance et défis
Growth factors
- Increased awareness about cardiovascular health – Increased public awareness about cardiovascular health due to media coverage, educational programs, and healthcare campaigns is a major factor driving the global cardiac management devices market. People are beginning to understand the importance of getting regular cardiac checkups and early intervention. According to data provided by CDC; between 2008 and 2014, the adjusted rate of adults who knew to call 9-1-1 when someone had a heart attack increased from 91.8% to 93.4% in 2014 and 94.9% in 2017 respectively.
With this increased awareness, people and healthcare providers are taking a proactive approach to heart health and implementing cutting-edge cardiac management devices. Early diagnosis, treatment, and cardiac rhythm management devices market expansion all benefit accordingly. - Growing Adoption of Wearable Technologies and Mobile Health Apps - The proliferation of wearable technologies, such as smartwatches , fitness trackers, and mobile health apps, offers new opportunities for continuous cardiac monitoring and personalized health management. Wearable devices with built-in sensors can track vital signs, heart rate variability, and activity levels, providing valuable data to assess cardiovascular health and detect early signs of heart abnormalities.
According to the National Heart, Lung, and Blood Institute, USA; one-third of Americans use wearables for health and fitness tracking. More than 80% of these individuals reportedly share device data with their doctors for health monitoring. - Digitalization and integration of health data - Heart rate manages
The expanding device market enables the integration of digital health solutions. Continuous monitoring and individualized care can be provided through remote monitoring, telemedicine, and data analytics, which can improve the efficiency of cardiac management.
The shift to digital health creates opportunities for collaboration between technology companies and device manufacturers. As seen, data integration software has been used by approximately 45% of healthcare services worldwide.
Challenges
- High cost of maintenance – A significant challenge is the high cost of advanced cardiac management devices, including initial implantation and ongoing maintenance. Access to these life-saving technologies, particularly in regions where healthcare budgets are under pressure, can be limited by affordability issues.
- Lack of Qualified Professionals - There is a shortage of healthcare professionals and physicians with the expertise to manage cardiac monitoring devices, including ECG devices, new pacemakers, and implanted defibrillators in patients with cardiac rhythm disorders or congestive heart failure. This shortage is widespread in most countries and will likely impact the cardiac rhythm management device market.
Marché des dispositifs de gestion du rythme cardiaque : principales conclusions
|
Reference year |
2023 |
|
Forecast year |
2024-2036 |
|
TCCA |
7% |
|
Base Year Market Size (2023) |
$18 billion |
|
Forecast Year Market Size (2036) |
$40 billion |
|
Regional scope |
|
Segmentation des dispositifs de gestion du rythme cardiaque
Product Type (Pacemakers, Defibrillators, Cardiac Resynchronization Devices)
The Pacemaker segment is poised to dominate over 38% of the cardiac rhythm management devices market share by 2036. The growth of the segment can be attributed to the widely adopted technology in the landscape. Pacemakers are a well-known and widely used technology. In 2022, the pacemaker segment accounted for approximately $5 billion in revenue. They have a long history of treating a variety of cardiac rhythm abnormalities and have proven to be highly effective in improving patient outcomes.
Pacemakers ensure that the heart beats at a regular and proper rhythm by providing reliable and continuous monitoring of electrical signals in the heart. As bradycardia becomes more common, people age, and pacemaker technology improves, there continues to be a significant demand for these devices. There are more than a million pacemakers installed worldwide each year.
End use (hospitals, cardiac care centers, outpatient medical centers, others)
By 2036, the hospital segment is expected to account for around 4% of the cardiac rhythm management devices market share . Hospitals provide comprehensive cardiac care, which includes post-operative care, diagnostics, and therapy. They ensure a holistic approach to patient management by having dedicated departments and healthcare specialists for cardiac rhythm management.
This category includes state-of-the-art facilities, such as intensive care units, operating rooms and cardiac catheterization laboratories, all equipped with the tools needed to perform complex cardiac operations. Qualified cardiologists and electrophysiologists with a focus on heart rhythm diagnosis and treatment
Anomalies are drawn to hospitals. These experts are essential to the process of selecting, implanting and monitoring cardiac rhythm monitoring devices.
Application (congestive heart failure, arrhythmias, bradycardia, tachycardia, others)
The arrhythmia segment is expected to gain a majority market share. This is primarily due to the increasing global prevalence of heart attacks and recurrent arrhythmia rates triggered by conditions like sedentary lifestyle issues. For instance, according to the Centers for Disease Prevention and Control (CDC), 12.1 million Americans would have atrial fibrillation (AFib) by 2030. Additionally, AFib was the underlying cause of death in 26,535 of the 183,321 deaths that occurred in 2019 as per death certificates.
Our in-depth analysis of cardiac rhythm management devices market includes the following segments:
|
Product type |
|
|
Request |
|
|
End use |
|
Souhaitez-vous personnaliser ce rapport de recherche selon vos besoins ? Notre équipe de recherche couvrira les informations dont vous avez besoin pour vous aider à prendre des décisions commerciales efficaces.
Personnaliser ce rapportIndustrie des dispositifs de gestion du rythme cardiaque - Synopsis régional
North American Market Statistics
The North America cardiac rhythm management devices market is estimated to dominate over 36% of the revenue share by 2036. The market growth in the region is also estimated to be driven by a well-developed healthcare infrastructure. The availability of highly skilled healthcare experts and advanced diagnostic and treatment facilities has led to a notable adoption of cardiovascular devices in the region. The United States constitutes the largest global market for pacemakers, accounting for approximately 50% of all sales. North America’s dominance in the market is also attributed to the existence of significant players in the market and continuous technological advancements.
According to the Centers for Disease Prevention and Control (CDC) statistics, in 2020, heart disease was the leading cause of death in the United States , with approximately 697,000 deaths. Moreover, heart disease imposes a high disease burden in the country, costing approximately $229 billion annually from 2017 to 2018. Therefore, the considerable disease burden, high prevalence, and mortality rate are expected to drive the market growth in the region. /p>
The increasing incidence of cardiovascular diseases, high frequency of cardiovascular disease risk factors such as diabetes, hypertension, and others, and the increasing use of minimally invasive procedures are the major factors propelling the market expansion in Canada . Cardiovascular diseases are the most common diseases in the country. For instance, according to data released by the Heart and Stroke Foundation of Canada in February 2022, 750,000 Canadians suffer from heart failure, and 100,000 new cases of this deadly disease are reported to the organization every year.
According to the same source, one in three Canadians has suffered from heart failure, either directly or through a close relative or friend. The demand for cardiovascular diagnostics is thus augmented by the growing prevalence of cardiovascular disorders in the country, which is expected to drive the cardiac rhythm management devices market throughout the forecast period.
APAC Market Analysis
The APAC region will also witness huge growth in the cardiac rhythm management devices market during the forecast period, with a CAGR of 5% from 2022, and will occupy the second position owing to The rapid expansion of the region can be attributed to increasing healthcare expenditure, improving healthcare facilities, and growing awareness about cardiovascular diseases.
The Asia Pacific region, which accounts for over 20% of global healthcare spending by 2030, will be the fastest growing region in healthcare spending. Due to their large patient population, growing geriatric population, and increasing rates of cardiac arrhythmias, countries such as China, India, and Japan are experiencing significant market expansion.
To boost domestic manufacturing of medical devices, the Chinese government launched the Volume-Based Procurement (VBP) law in 2020. According to the January 2022 article “Volume-Based Procurement Shakes Up China’s High-Value Medical Device Market: High-value medical supplies have been subjected to VBP in China, starting with coronary stents.
to combat the rising prices of high-end medical supplies. Therefore, the Chinese government’s initiative is expected to present opportunities for the stent segment. This is expected to fuel the expansion of the cardiac rhythm management devices market.
Increasing research and development activities, along with the launch of new devices and initiatives by various organizations, are estimated to drive the market growth in Korea. For instance, in February 2021, Seoul National University Hospital implanted a wireless pacemaker in patients suffering from arrhythmia in Korea, demonstrating the growth potential of the segment during the forecast period.
In March 2022, Rampart IC signed an exclusive distribution agreement with Japan Lifeline (JLL), securing distribution in the Japanese market. This partnership is expected to increase the adoption of cardiovascular devices in Japan, thereby driving the growth of the cardiac rhythm management devices market.
Entreprises Dominant les appareils de gestion du rythme cardiaque Paysage
- Vitatron Holding BV
- Company Overview
- Operational strategy
- Main products offered
- Financial results
- Key performance indicators
- Risk analysis
- Recent development
- Regional presence
- SWOT Analysis
- Medtronic
- Biotronik
- Abbott
- ABIOMED
- Stryker Company
- Friendship.
- © BPL Medical Technologies
- OSYPKA MEDICAL
- MicroPort Scientific Society
The cardiac rhythm management devices market is dominated by key market players who are gaining traction in the market by adopting several strategies including merger and acquisitions.
In the News
- Medtronics PulseSelect Pulsed Field Ablation System (PFA) has been approved by the U.S. Food and Drug Administration (FDA) to treat paroxysmal and persistent atrial fibrillation (AF), according to an announcement by the company. Following the PulseSelect PFA System’s November European CE (Conformité Européenne) Mark, this is the first PFA technology to be approved by the FDA.
- Abbott announced that the U.S. Food and Drug Administration has approved the AssertIQTM insertable cardiac monitor, providing physicians with a new option for the diagnostic evaluation and long-term monitoring of patients with irregular heart rhythms. This approval builds on Abbott’s portfolio of connected medical devices that can help physicians better manage and treat their patients remotely.
Crédits des auteurs: Radhika Pawar
- Report ID: 6044
- Published Date: May 22, 2024
- Report Format: PDF, PPT
